Abstract

Chronic hepatitis C infection (HCV) activates a systemic cell-mediated immune response characterized by the production of IFNγ and an innate immune response addressed by the activation of TLR signaling. We aimed to investigate whether HCV eradication by direct acting antivirals (DAA) leads to a recovery in cell-mediated immune response and TLR expression and functionality. Blood samples were obtained in HCV infected patients before DAA treatment and at week +48 after the end of treatment. Results were compared to healthy controls. Cell surface expression of TLR8 was assessed on peripheral blood mononuclear cells (PBMCs) by flow cytometry. Freshly isolated PBMCs were cultured with specific TLR8 agonists and intracellular production of cytokines was determined by flow-cytometry after ex vivo TLR8 activation with ssRNA 40. Production of IFNγ, IL2 and IL17 was assessed by flow cytometry in T cells after polyclonal activation. Included were 50 HCV-infected patients and 15 controls. TLR8 expression in PBMCs was significantly increased before treatment and recovered normal levels at week +48. Production of IL1b, IL6 and TNFα dependent on the activation of TLR8 in PBMCs was also increased in patients before DAA treatment, with a significant reduction at week +48. Combined expression of IFNγ and IL2 in CD4+ T cells in HCV-infected patients was significantly increased compared to controls and recovered normal levels at week +48. DAA-mediated clearance of HCV is associated with a decreased expression and activation of TLR8 in PBMCs until healthy control levels which is accompanied by a reduction in the Th1 response.

Highlights

  • Chronic hepatitis C virus (HCV) infection has been the leading cause of chronic liver disease, cirrhosis and liver transplant indication worldwide in the past decades [1,2].the appearance of effective interferon free direct acting anti-viral (DAA)treatment regimens has dramatically changed the natural history and epidemiology of HCV infection [3,4]

  • Patients included in this study were drawn from a sample of chronically infected hepatitis C virus (HCV) candidates to initiate an interferon-free treatment regimen referred to our Hepatology Unit from 2015 to 2017

  • We found a significant higher expression profile of TLR8 in the three cell lines analyzed (B cells, T cells, and monocytes) in HCV infected patients compared to healthy controls (Figure 2A)

Read more

Summary

Introduction

Chronic hepatitis C virus (HCV) infection has been the leading cause of chronic liver disease, cirrhosis and liver transplant indication worldwide in the past decades [1,2].the appearance of effective interferon free direct acting anti-viral (DAA)treatment regimens has dramatically changed the natural history and epidemiology of HCV infection [3,4]. Chronic hepatitis C virus (HCV) infection has been the leading cause of chronic liver disease, cirrhosis and liver transplant indication worldwide in the past decades [1,2]. Progression from chronic hepatitis to different grades of fibrosis and cirrhosis may take several decades [5]. This progression is driven by an immune activation that entails a chronic low-grade inflammatory response that seems to be mediated at least in part by an interferon-driven innate immune response [6]. Genetic variations in TLR8 have been associated with the clearance and progression of HCV infection with some gender influence [10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call